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Improving HPV Vaccination Rates
Abstract
Despite national guidelines and proven health benefits, vaccination rates for the human papillomavirus
(HPV) remain far below those of other vaccines recommended for adolescents. HPV is the most common
sexually transmitted infection in the U.S; it is responsible for about 25,000 new cancers each year. A series of
three shots is recommended for all girls and boys at age 11-12, but significant barriers exist to starting and
finishing this series. This Issue Brief examines some of the barriers and summarizes a successful, multipronged
clinical intervention to improve vaccination rates.
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Improving HPV Vaccination Rates
Editor’s Note: Despite national guidelines and proven health benefits, vaccination 
rates for the human papillomavirus (HPV) remain far below those of other vaccines 
recommended for adolescents. HPV is the most common sexually transmitted 
infection in the U.S; it is responsible for about 25,000 new cancers each year. A series 
of three shots is recommended for all girls and boys at age 11-12, but significant 
barriers exist to starting and finishing this series. This Issue Brief examines some of the 
barriers and summarizes a successful, multipronged clinical intervention to improve 
vaccination rates. 
The HPV vaccine can prevent about 70% of all cervical cancer, 90% of all genital 
warts, and substantial numbers of oropharangeal cancers. In 2006, the national 
Advisory Committee on Immunization Practices (ACIP) recommended the HPV 
vaccination for all girls aged 11-12 years, and extended that recommendation to 
boys aged 11-12 years in 2011. These recommendations are designed to promote 
vaccination when the vaccine is most effective: before the initiation of sexual activity 
and exposure to HPV.
• HPV vaccination rates are low. In 2012 only 54% of all girls in the US – and 
substantially fewer boys – had received the first dose. Just one-third of girls ages 
13-17 were fully vaccinated.
• Despite the low uptake of the vaccine, it is still having an impact on infection 
rates. In the first four years of its introduction, the prevalence of vaccine-type HPV 
infection decreased 56% among girls ages 14-19. 
• Parental concerns, clinician beliefs and practice styles, and adolescents’ patterns of 
health care utilization all play a role in limiting the use of the HPV vaccine. 
Parents often delay HPV vaccination because they are reluctant to immunize 
prepubertal girls against sexually transmitted infections and because they have 
doubts about long-term safety and efficacy.
• Studies show that if clinicians recommend it, parents are more likely to have their 
children vaccinated for HPV. However, parents’ beliefs about the vaccine may 
also influence clinicians’ intentions to vaccinate: clinicians can be reluctant to 
recommend vaccination due to perceived parental concerns.
HPV vaccination rates 
remain low
Using this information, Fiks and colleagues designed and tested an intervention using 
electronic medical record (EMR) data to improve HPV vaccination rates. 
The “decision support” system targeted both families and clinicians.
• The clinician-focused intervention had three components: (1) electronic alerts for 
routine adolescent vaccinations when a patient’s EMR was opened, (2) a 
one-hour online or in-person educational presentation about vaccine safety, efficacy, 
and strategies for overcoming barriers to vaccine receipt, with site-specific HPV 
vaccination rates, and (3) three quarterly feedback reports on individual, practice, 
and network rates.
• The family-focused intervention featured automated reminder calls about 
well-visit or follow-up appointments. The calls also emphasized that the vaccine 
was recommended by the clinician and referred families to a website containing 
information on adolescent vaccines.
• From May 2010-May 2011, CHOP primary care practices sites were randomized 
to either receive the clinician-focused intervention or no intervention. Within these 
practice sites, 22,486 girls (11-17 years) due for HPV vaccine dose 1, 2, or 3 were 
randomized to either receive the family-focused intervention or usual care. 
At the start, 79% of the girls had not received any doses of the vaccine.
Study evaluates automated 
decision support tool for both 
clinicians and families
Interviews shed light on 
how clinicians, parents, 
and adolescents talk about 
vaccination
Given that parents, teens, and clinicians all report that their views are influenced by 
each other, Hughes and colleagues conducted interviews to understand what happens 
at the point of care. They interviewed 20 adolescent-mother-clinician triads (60 
total interviews) within primary care sites at The Children’s Hospital of Philadelphia 
(CHOP) and identified three main themes:
• Parents often delayed, instead of completely refused, vaccination, and when they 
expressed reluctance, clinicians were hesitant to engage them in discussion. 
• Clinicians used one of two strategies to present the HPV vaccine, either describing 
it as a routine vaccination without offering any additional information, or 
describing it as an optional vaccination while highlighting its risks and benefits.
• Teens viewed themselves as passive participants in the decision-making process, 
even when parents and clinicians reported including them.
After 12 months, the combined clinician and family-focused intervention resulted in 
significantly higher HPV vaccination rates compared to usual care, and reduced delays 
in initiating vaccination. 
• In the usual-care group, vaccination rates for HPV dose #1, #2, and #3 were 16%, 
65%, and 63%. The combined intervention increased those rates by 9, 8, and 
13 percentage points, respectively. The clinician-focused intervention was most 
effective for initiating the HPV series (receiving HPV #1), whereas the 
family-focused intervention supported completion of the series (receiving HPV #2 
and #3), as shown below.
Intervention effective in 
improving rates of starting 
and completing HPV 
vaccination
 HPV #1 HPV #2  HPV #3 
  (having received #1) (having received #2)
 Combined intervention 25%* 73%* 76%*
 Clinician-focused 24%* 64% 67%
 Family-focused 18% 71%* 73%*
 Usual care 16% 65% 63%
 *Results significantly different from usual care
Continued on back.
Parents find decision supports 
tools acceptable
How did parents react to the family-focused intervention? Mayne and colleagues 
called parents shortly after a preventive care visit and asked about the acceptability 
of the family-focused automated reminder phone calls and if the calls had affected 
parents’ information-seeking behavior, communication, and vaccine-related 
decision-making. 
• 162 parents of girls who were due for HPV #1 completed the telephone interview. 
Of these parents, 80 had initially been randomized to receive the family-focused 
intervention. 
• Of the 80 parents in the intervention group, 46% (37) remembered receiving an 
automated reminder call. Among those who did remember it, the vast majority 
found the call acceptable: only 2 parents reacted negatively, describing the call as 
“pushy” or “inappropriate.” 
• Of the 37 parents who remembered the call, 27% said it positively affected the 
likelihood they would have their child vaccinated. 
• About half of the 37 parents remembered hearing the study’s educational website 
mentioned during the automated call, but no one had actually visited it. However, 
43% of the parents who remembered the call reported that it prompted them to 
seek information about the HPV vaccine on their own (e.g., through discussion 
with others or different websites). 
• Parents in a practice that received the clinician-focused intervention were more 
likely to report that the clinician had discussed HPV vaccination at the visit 
(84% vs. 70%). 
POLICY IMPLICATIONS These series of studies show that decisions about HPV vaccines can be improved, 
and rates of HPV vaccines increased, with a low-cost intervention that supports both 
clinicians and families with information and reminders. 
• The results highlight the central role that the clinician plays in promoting the 
receipt of the initial dose of HPV vaccine, and the central role families play in 
assuring that the entire HPV series is completed. A focus on either one alone is 
likely to be inadequate to fully realize the benefits of vaccination.
• The automated decision support system is driven by the electronic medical record. 
To the extent that EMRs are being adopted widely, the intervention can be built 
into primary care practices easily and cost-effectively.
• Families find clinical decision support programs based on EMR data acceptable. 
These programs may promote information-seeking, discussion with others, and 
productive decision-making in relation to the HPV vaccine. Phone call reminders 
• The intervention also was effective in decreasing time to vaccine receipt. Compared 
to usual care, adolescents in the combined intervention group were, on average, 
151, 68, and 93 days faster at receiving vaccine doses 1, 2, and 3, respectively.
• The incremental cost of the more effective interventions (compared to usual care) 
was low: $6 per additional girl receiving HPV #1 in the clinician intervention, and 
$10 and $6 per girl in the family intervention receiving doses #2 and 3, respectively. 
The combined intervention added $24 compared with the clinician intervention for 
HPV #1, and $42 and $189 compared with the family intervention for HPV 
#2 and 3.
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POLICY IMPLICATIONS
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may be an effective short-term way of fostering information-seeking and vaccine-
related discussion, but they may not be the best method of directing parents to 
specific educational content on the internet; other secure methods of reaching 
parents (e.g., email, text messaging, and patient portals) should be explored. 
• Given the success of this intervention, future research should be directed at 
adapting it to support evidenced-based care in varied clinical contexts. 
